Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18025742 | 0.87 | PLAT (0.35) | HTTLMNAMAPTHPGDMEN1 | |
| SCHEMBL6853026 | 0.79 | LMNA (0.40) | HTTLMNAMAPTHPGDMEN1 | |
| SCHEMBL18426329 | 0.72 | S1PR3 (0.32) | GAA | |
| SCHEMBL15566870 | 0.71 | MAPT (0.35) | HTTMAPTHPGDMEN1KMT2A | |
| SCHEMBL25623412 | 0.70 | JAK2 (0.34) | — | |
| SCHEMBL7368052 | 0.69 | LMNA (0.36) | HTTLMNAMAPTHPGDMEN1 | |
| SCHEMBL4001733 | 0.69 | SMN1; SMN2 (0.52) | LMNAMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL6366582 | 0.68 | HCAR2 (0.39) | HTTLMNAMAPTHPGDMEN1 | |
| SCHEMBL17619252 | 0.68 | HTT (0.45) | HTTLMNAMAPTHPGDMEN1 | |
| SCHEMBL15566566 | 0.66 | SMN1; SMN2 (0.40) | HTTLMNAMAPTHPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6777416-B2 | CYCLIC GUANOSINE 3',5'-MONOPHOPHATE METABOLIZING PHOSPHO-DIESTERASE INHIBITORS; HAVING HYDROXY- OR ALKOXY- BENZENE SULFONAMIDE FUNCTIONALITY | BAYER AKTIENGESELLSCHAFT (DE) | 2004-08-17 | — | — | US | disclosed |
| US-20030149033-A1 | Isoxazolo pyrimidinones and the use thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2003-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149033-A1 | Isoxazolo pyrimidinones and the use thereof | DHFR, HPRT1, DPYD | HTT 3303/4885LMNA 4415/4885MAPT 3299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.